Century Therapeutics Inc. (NASDAQ: IPSC) Stock Information | RedChip

Century Therapeutics Inc. (NASDAQ: IPSC) Listen to this Section


$1.61
-0.0550 ( -3.31% ) 327.5K

Century Therapeutics Inc is a biotechnology company specializes in leveraging adult stem cells to develop advanced cell therapy products targeting cancer, autoimmune, and inflammatory diseases. Their innovative approach involves a genetically engineered allogeneic cell therapy platform comprising induced pluripotent stem cells (iPSCs), CRISPR-mediated precision gene editing, proprietary chimeric antigen receptors (CARs), Allo-EvasionTM technology, and cutting-edge manufacturing capabilities. This comprehensive platform aims to overcome the limitations of first-generation cell therapies by optimizing cell product performance, preventing rejection by the host immune system, and minimizing development and supply risks.

Market Data


Open


$1.61

Previous close


$1.66

Volume


327.5K

Market cap


$136.39M

Day range


$1.56 - $2.12

52 week range


$1.28 - $5.51

Insider Ownership Transactions

Total Amount Purchased: -1,310,233.00 | $ -2,102,923.97

Date Type Amount Purchased Purchaser
2024-03-11 Sale -24000.00 Levitsky Hyam
2024-03-11 Sale -24000.00 Farid Adrienne
2024-03-11 Sale -24000.00 Russotti Gregory
2024-03-11 Sale -14000.00 Carr Douglas
2024-03-08 Sale -30684.00 Farid Adrienne
2024-02-21 Sale -485.00 Farid Adrienne
2024-02-07 Sale -643.00 Carr Douglas
2024-02-07 Sale -2035.00 Farid Adrienne
2023-12-06 Sale -1173775.00 Pfeiffenberger Brent
2023-11-03 Sale -16611.00 Carr Douglas

SEC Fillings


Form Type Description Pages Date
4 Insider transactions 1 May 21, 2024
10-q Quarterly Reports 89 May 09, 2024
8-k 8K-related 15 May 09, 2024
4 Insider transactions 1 May 07, 2024
4 Insider transactions 1 May 07, 2024
4 Insider transactions 1 May 07, 2024
ars Annual reports 1 Apr 26, 2024
def Proxies and info statements 10 Apr 26, 2024
4 Insider transactions 1 Apr 24, 2024
pre Proxies and info statements 10 Apr 16, 2024

Latest News


Terms and Agreement

Please agree to the terms to continue using the chat feature.